Unicycive Therapeutics Inc
UNCY6.690USD
+0.500+8.08%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
139.49MMarket Cap
LossP/E TTM
More Details of Unicycive Therapeutics Inc Company
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc Info
Ticker SymbolUNCY
Company nameUnicycive Therapeutics Inc
IPO dateJun 17, 2021
CEOGupta (Shalabh)
Number of employees22
Security typeOrdinary Share
Fiscal year-endJun 17
Address4300 El Camino Real, Suite 210
CityLOS ALTOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94022
Phone16503840642
Websitehttps://unicycive.com/
Ticker SymbolUNCY
IPO dateJun 17, 2021
CEOGupta (Shalabh)
Company Executives of Unicycive Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
8.33%
Millennium Management LLC
5.46%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
Other
73.49%
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
8.33%
Millennium Management LLC
5.46%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
Other
73.49%
Shareholder Types
Shareholders
Proportion
Hedge Fund
19.90%
Venture Capital
10.71%
Investment Advisor
4.05%
Individual Investor
2.93%
Investment Advisor/Hedge Fund
1.55%
Research Firm
0.29%
Other
60.57%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
65
6.67M
31.03%
-253.32K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Vivo Capital, LLC
1.79M
8.33%
+652.90K
+57.42%
Sep 30, 2025
Octagon Capital Advisors LP
1.00M
4.65%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
939.20K
4.37%
--
--
Sep 30, 2025
Great Point Partners, LLC
796.56K
3.71%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
658.88K
3.07%
+52.92K
+8.73%
Sep 30, 2025
Gupta (Shalabh K)
597.25K
2.78%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
2.2%
+1.00
+0.00%
Sep 30, 2025
Rosalind Advisors, Inc.
242.49K
1.13%
+242.49K
--
Apr 30, 2025
Geode Capital Management, L.L.C.
125.73K
0.58%
+66.94K
+113.87%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 17, 2025
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Jun 17, 2025
Merger
10→1
